AIM at Melanoma Celebrating 20 Year Anniversary
Twenty years ago, the AIM at Melanoma Foundation was established by a determined woman with a relentless drive to find…
01/11/2024
AIM at Melanoma Celebrating 20 Year Anniversary
Twenty years ago, the AIM at Melanoma Foundation was established by a determined woman with a relentless drive to find…
01/09/2024
Vitality Should be on the Table for All Cancer Survivors
Join us as we dive deep into the emotional path of survivorship. Dr. Liu sat down with Samantha Siegel, MD,…
|
01/02/2024
Clinical Trials Saved My Life
By Mara Klecker When Barbara Hunter found out her melanoma had returned as Stage IV and was in her liver,…
|
12/19/2023
Navigating Melanoma During the Holidays
The holiday season is often portrayed as a time of joy, love, and celebration. However, for melanoma cancer patients, it…
|
12/18/2023
The Clinical Trial Experience: A Patient’s Perspective
In 2010, Mary Elizabeth Williams was diagnosed with metastatic melanoma. The following year, she was offered the opportunity to participate…
|
12/05/2023
Celebrate Survivorship – Give Towards Melanoma Research
Melanoma knows no boundaries. It’s a disease that affects people of all ages, races, and backgrounds. And it’s a devastating…
|
11/14/2023
Melanoma Cancer and Financial Toxicity
While being diagnosed with cancer alone can put a person under tremendous amounts of mental and emotional stress, the additional…
|
10/31/2023
National Family Caregiver Month
National Caregiver Month is observed every November to honor and appreciate the selfless individuals who dedicate their lives to caring…
|
10/23/2023
Immunocore Presents Three-Year Overall Survival Data from the KIMMTRAK Phase 3 Trial
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial Published: Oct 21, 2023 Data published in New…
|
|
10/15/2023
Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
October 13, 2023 17:30 ET| Source: Bristol Myers Squibb In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant…
|
|
Recent Posts
Apr. 02, 2026
Uveal Melanoma Webinar: Part II — Navigating Treatment in the Metastatic Setting
Mar. 26, 2026
Wade Watson, Stage III Melanoma Survivor
Mar. 03, 2026
Cancer is More Than a Diagnosis: Mind, Meaning, and Healing
Feb. 19, 2026
Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN®
Feb. 05, 2026